1.085

0.93% -0.005

Fate Therapeutics Inc (FATE)

Overview News Price History Option Chain Financials Discussions Forecast

Fate Therapeutics Inc stock is traded at $1.085, with a volume of 6.13M. It is down -0.93% in the last 24 hours and down -16.93% over the past month. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Previous Close:

$1.09

Open:

$1.07

24h Volume:

6.13M

Relative Volume:

2.05

Market Cap:

$124.14M

Revenue:

$13.45M

Net Income/Loss:

$-178.23M

P/E Ratio:

-0.6576

EPS:

-1.65

Net Cash Flow:

$-132.53M

1W Performance:

-23.95%

1M Performance:

-16.93%

6M Performance:

-69.23%

1Y Performance:

-84.88%

1-Day Range:

$1.00

$1.13

1-Week Range:

$1.00

$1.43

52-Week Range:

$1.00

$8.83

Fate Therapeutics Inc Stock (FATE) Company Profile

Name

Fate Therapeutics Inc

Sector

Healthcare (1189)

Industry

Biotechnology (675)

Phone

858.875.1803

Address

12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA

Employee

181

Twitter

@fatethx

Next Earnings Date

2024-11-06

Latest SEC Filings

FATE's Discussions on Twitter

Compare FATE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FATE Fate Therapeutics Inc	1.085	124.14M	13.45M	-178.23M	-132.53M	-1.65
VRTX Vertex Pharmaceuticals Inc	476.05	121.85B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	696.71	76.83B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	616.78	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	242.02	30.69B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	268.30	29.71B	3.32B	-860.46M	-1.04B	-8.32

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral
Jan-06-23	Downgrade	Stifel	Buy → Hold
Jan-06-23	Downgrade	Truist	Buy → Hold
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight
Oct-10-22	Initiated	Canaccord Genuity	Buy
Aug-18-22	Resumed	Wells Fargo	Overweight
Jul-28-22	Initiated	Needham	Hold
Jul-11-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-11-22	Resumed	BMO Capital Markets	Market Perform
Dec-15-21	Upgrade	Wedbush	Neutral → Outperform
Dec-07-21	Initiated	Cowen	Outperform
Nov-09-21	Upgrade	Citigroup	Neutral → Buy
Aug-26-21	Initiated	Morgan Stanley	Equal-Weight
Jun-07-21	Upgrade	H.C. Wainwright	Neutral → Buy
May-07-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Jefferies	Buy
Feb-26-21	Initiated	BofA Securities	Buy
Feb-26-21	Downgrade	Wedbush	Outperform → Neutral
Feb-11-21	Downgrade	Citigroup	Buy → Neutral
Jan-27-21	Resumed	H.C. Wainwright	Neutral
May-13-20	Initiated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Overweight
Jan-09-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
Dec-30-19	Reiterated	Mizuho	Buy
Dec-09-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-12-19	Initiated	SunTrust	Buy
Nov-06-19	Downgrade	Wells Fargo	Outperform → Market Perform
Oct-01-19	Initiated	Stifel	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	Cantor Fitzgerald	Overweight
Jul-12-19	Initiated	Oppenheimer	Outperform
Jun-13-19	Initiated	Mizuho	Buy
Jun-07-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Buy
May-24-19	Resumed	Citigroup	Buy
Mar-28-19	Initiated	SVB Leerink	Outperform
Jan-03-19	Downgrade	Stephens	Overweight → Equal-Weight
Nov-05-18	Initiated	Jefferies	Buy
Aug-01-18	Initiated	Citigroup	Buy
Mar-06-18	Downgrade	H.C. Wainwright	Buy → Neutral

View All

Fate Therapeutics Inc Stock (FATE) Latest News

01:00 AM

NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.

01:00 AM

Feb 22, 2025

Fate Therapeutics (FATE) Projected to Post Earnings on Monday - Defense World

Feb 22, 2025

Feb 20, 2025

iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World

Feb 20, 2025

Fate Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire

Feb 20, 2025

Feb 18, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Feb 18, 2025

Q1 Earnings Estimate for FATE Issued By Leerink Partnrs - MarketBeat

Feb 18, 2025

Feb 17, 2025

Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know - Yahoo Finance

Feb 17, 2025

Fate Therapeutics (FATE) Projected to Post Quarterly Earnings on Monday - MarketBeat

Feb 17, 2025

FY2024 Earnings Forecast for FATE Issued By Leerink Partnrs - Defense World

Feb 17, 2025

Feb 16, 2025

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Fate Therapeutics, Inc. (FATE) Investors to Deadline in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm’s Attorneys - accessnewswire.com

Feb 16, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of “Hold” from Analysts - Defense World

Feb 16, 2025

Feb 15, 2025

What is Leerink Partnrs’ Estimate for FATE Q1 Earnings? - Defense World

Feb 15, 2025

Feb 14, 2025

Fate Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire

Feb 14, 2025

SG Americas Securities LLC Acquires 10,511 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Feb 14, 2025

Feb 10, 2025

Navigating FATE Stock: Fate Therapeutics Inc Journey - The InvestChronicle

Feb 10, 2025

Analysts review Fate Therapeutics Inc’s rating - Knox Daily

Feb 10, 2025

Feb 06, 2025

CRISPR and Cas Gene Market May Set a New Epic Growth Story | Fate Therapeutics, Cellectis, Synlogic - Newstrail

Feb 06, 2025

Take off with Fate Therapeutics Inc (FATE): Get ready for trading - SETE News

Feb 06, 2025